$BRNS
Barinthus Biotherapeutics plc. Stock $brns

$brns Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000182818524000011 Filed on March 20, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$802.0K
YoY Change	-100.0%	-100.0%	-98.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.994M	$13.62M	$39.84M
YoY Change	-50.62%	-32.96%	523.12%
% of Gross Profit
Research & Development	$11.13M	$6.373M	$44.87M
YoY Change	13.36%	-47.7%	5.96%
% of Gross Profit
Depreciation & Amortization	$1.430M	$1.435M	$5.429M
YoY Change	17.12%	21.92%	25.58%
% of Gross Profit
Operating Expenses	$17.12M	$19.99M	$84.72M
YoY Change	-22.02%	-38.49%	73.8%
Operating Profit	-$16.91M		-$83.91M
YoY Change	-21.27%		1976.57%
Interest Expense	$12.00K	$564.0K	$28.00K
YoY Change	-99.24%	-74.91%	47.37%
% of Operating Profit
Other Income/Expense, Net	$1.357M	$1.314M	$7.392M
YoY Change	-50.56%	116.83%	51.13%
Pretax Income	-$15.56M	-$18.11M	-$76.52M
YoY Change	-16.98%	-21.88%	-9102.59%
Income Tax	-$37.00K	-$820.0K	-$3.075M
% Of Pretax Income
Net Earnings	-$15.49M	-$17.29M	-$73.35M
YoY Change	-14.8%	-18.39%	-1473.03%
Net Earnings / Revenue			-9145.51%
Basic Earnings Per Share	-$0.40		-$1.91
Diluted Earnings Per Share	-$0.40	-$0.45	-$1.91
COMMON SHARES
Basic Shares Outstanding	38.92M shares	38.57M	38.39M shares
Diluted Shares Outstanding	38.77M shares		38.39M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$130.0M	$142.1M	$142.1M
YoY Change	-32.07%	-26.9%	-26.9%
Cash & Equivalents	$130.0M	$142.1M	$142.1M
Short-Term Investments
Other Short-Term Assets	$1.675M	$1.474M	$6.876M
YoY Change	205.1%	161.81%	-16.35%
Inventory
Prepaid Expenses	$5.093M	$5.402M
Receivables		$0.00	$0.00
Other Receivables		$7.939M	$7.939M
Total Short-Term Assets	$143.1M	$156.9M	$156.9M
YoY Change	-28.67%	-26.35%	-26.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.53M	$11.82M	$19.40M
YoY Change	-9.28%	48.56%	23.5%
Goodwill	$12.21M	$12.21M
YoY Change	0.0%	0.0%
Intangibles	$24.32M	$25.11M
YoY Change	-11.51%	-11.18%
Long-Term Investments
YoY Change
Other Assets	$885.0K	$882.0K	$882.0K
YoY Change	-13.91%	-9.63%	-9.63%
Total Long-Term Assets	$56.35M	$57.60M	$57.60M
YoY Change	-7.85%	0.76%	0.76%
TOTAL ASSETS
Total Short-Term Assets	$143.1M	$156.9M	$156.9M
Total Long-Term Assets	$56.35M	$57.60M	$57.60M
Total Assets	$199.5M	$214.5M	$214.5M
YoY Change	-23.81%	-20.61%	-20.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.162M	$1.601M	$1.601M
YoY Change	-73.15%	-57.28%	-57.28%
Accrued Expenses	$10.24M	$11.00M	$11.00M
YoY Change	33.65%	29.47%	29.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.84M	$12.60M	$12.60M
YoY Change	7.07%	2.91%	2.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.330M	$1.325M	$14.34M
YoY Change	1.22%	37.31%	30.17%
Total Long-Term Liabilities	$1.330M	$1.325M	$14.34M
YoY Change	1.22%	37.31%	30.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.84M	$12.60M	$12.60M
Total Long-Term Liabilities	$1.330M	$1.325M	$14.34M
Total Liabilities	$27.47M	$27.51M	$27.72M
YoY Change	-2.76%	1.88%	1.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$192.1M	-$176.6M
YoY Change	58.24%	71.12%
Common Stock	$1.000K	$1.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$171.8M	$186.8M	$186.8M
YoY Change
Total Liabilities & Shareholders Equity	$199.5M	$214.5M	$214.5M
YoY Change	-23.81%	-20.61%	-20.61%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$15.49M	-$17.29M	-$73.35M
YoY Change	-14.8%	-18.39%	-1473.03%
Depreciation, Depletion And Amortization	$1.430M	$1.435M	$5.429M
YoY Change	17.12%	21.92%	25.58%
Cash From Operating Activities	-$11.82M	-$19.60M	-$50.93M
YoY Change	272.46%	72.82%	252.89%
INVESTING ACTIVITIES
Capital Expenditures	$308.0K	-$153.0K	$5.413M
YoY Change	-87.71%	-126.11%	-11.81%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$308.0K	$153.0K	-$5.413M
YoY Change	-87.71%	-126.11%	-5.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$2.035M
YoY Change			320.45%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$503.0K	109.0K	$1.872M
YoY Change	-70.22%	-77.48%	476.0%
NET CHANGE
Cash From Operating Activities	-$11.82M	-19.60M	-$50.93M
Cash From Investing Activities	-$308.0K	153.0K	-$5.413M
Cash From Financing Activities	$503.0K	109.0K	$1.872M
Net Change In Cash	-$12.12M	-19.34M	-$52.30M
YoY Change	296.43%	68.99%	165.88%
FREE CASH FLOW
Cash From Operating Activities	-$11.82M	-$19.60M	-$50.93M
Capital Expenditures	$308.0K	-$153.0K	$5.413M
Free Cash Flow	-$12.13M	-$19.45M	-$56.34M
YoY Change	113.52%	63.05%	173.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001828185
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40367
CY2023	dei	Entity Registrant Name EntityRegistrantName	BARINTHUS BIOTHERAPEUTICS PLC
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Unit 6-10, Zeus Building
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Rutherford Avenue
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Harwell,Didcot
CY2023	dei	Entity Address Country EntityAddressCountry	GB
CY2023	dei	City Area Code CityAreaCode	+44 (0)
CY2023	dei	Local Phone Number LocalPhoneNumber	1865 818 808
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	79400000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38921212	shares
CY2023	dei	Auditor Firm AuditorFirmId	876
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	United Kingdom
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142090000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	194385000	usd
CY2023Q4	brns	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	4908000	usd
CY2022Q4	brns	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	4541000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9907000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8268000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	156905000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	213041000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	12209000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	12209000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11821000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7957000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25108000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	28269000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7581000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7753000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	882000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	976000	usd
CY2023Q4	us-gaap	Assets Assets	214506000	usd
CY2022Q4	us-gaap	Assets Assets	270205000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1601000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3748000	usd
CY2023Q4	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	9212000	usd
CY2022Q4	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	8061000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1785000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	433000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12598000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12242000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11191000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8340000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1823000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1711000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1325000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	965000	usd
CY2023Q4	brns	Deferred Tax Liability Net DeferredTaxLiabilityNet	574000	usd
CY2022Q4	brns	Deferred Tax Liability Net DeferredTaxLiabilityNet	3746000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	27511000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	27004000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000025
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000025
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38643540	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38643540	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	38643540	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	37683531	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37683531	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37683531	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	386602000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	379504000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176590000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103243000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-23315000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-33460000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	186784000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	242896000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	211000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	305000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	186995000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	243201000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	214506000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	270205000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	802000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44703000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44874000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42350000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39842000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6394000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	84716000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	48744000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-83914000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4041000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	2877000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	3103000	usd
CY2023	us-gaap	Interest Expense InterestExpense	28000	usd
CY2022	us-gaap	Interest Expense InterestExpense	19000	usd
CY2023	brns	Research And Development Incentive Income Expense ResearchAndDevelopmentIncentiveIncomeExpense	3461000	usd
CY2022	brns	Research And Development Incentive Income Expense ResearchAndDevelopmentIncentiveIncomeExpense	1240000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1082000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	567000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7392000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4891000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76522000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	850000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4471000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-73347000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38386491	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37248126	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38386491	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38169307	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.91
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.91
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2023	us-gaap	Profit Loss ProfitLoss	-73447000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	5321000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-25083000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-63296000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-19762000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-94000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-132000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63202000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19630000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	243201000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5055000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2035000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	10151000	usd
CY2023	brns	Shares Cancelled During Period Value Deferred Shares SharesCancelledDuringPeriodValueDeferredShares	0	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-73447000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	186995000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	252562000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9877000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	484000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-25083000	usd
CY2022	brns	Adjustments To Additional Paid In Capital Measurement Period Adjustments In Business Combination AdjustmentsToAdditionalPaidInCapitalMeasurementPeriodAdjustmentsInBusinessCombination	40000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	5321000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	243201000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-73447000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	5321000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	5055000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	9877000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5429000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4323000	usd
CY2023	brns	Non Cash Lease Expenses NonCashLeaseExpenses	1328000	usd
CY2022	brns	Non Cash Lease Expenses NonCashLeaseExpenses	1216000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-7531000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	24905000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	55000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-73000	usd
CY2023	brns	Non Cash Interest Expense On Convertible Loan Notes NonCashInterestExpenseOnConvertibleLoanNotes	28000	usd
CY2022	brns	Non Cash Interest Expense On Convertible Loan Notes NonCashInterestExpenseOnConvertibleLoanNotes	19000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3075000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4337000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	348000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5800000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5833000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2200000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2170000	usd
CY2023	brns	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	127000	usd
CY2022	brns	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	-1158000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3378000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1140000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1993000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	751000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-183000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-445000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-128000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	387000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50925000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14431000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	388000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5413000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6138000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5413000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5750000	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2035000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	484000	usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	163000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	159000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1872000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	325000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2171000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	187000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-52295000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19669000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194385000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	214054000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142090000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194385000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	87000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	559000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2400000	usd
CY2023	brns	Asset Retirement Obligations AssetRetirementObligations	287000	usd
CY2022	brns	Asset Retirement Obligations AssetRetirementObligations	999000	usd
CY2023	brns	Changes To Right Of Use Asset Resulting From Lease Reassessment Event ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent	88000	usd
CY2022	brns	Changes To Right Of Use Asset Resulting From Lease Reassessment Event ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent	-207000	usd
CY2023	brns	Non Cash Investing And Financing Activity Of Measurement Period Adjustments NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments	0	usd
CY2022	brns	Non Cash Investing And Financing Activity Of Measurement Period Adjustments NonCashInvestingAndFinancingActivityOfMeasurementPeriodAdjustments	-38000	usd
CY2023	brns	Contingent Consideration Settled In Equity ContingentConsiderationSettledInEquity	0	usd
CY2022	brns	Contingent Consideration Settled In Equity ContingentConsiderationSettledInEquity	78000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142100000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-176600000	usd
CY2023	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Guarantees and indemnifications</span></div>As permitted under the laws of England and Wales, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company.
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue, income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, including those related to fair value of contingent consideration and impairment of goodwill and intangible assets. The Company’s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.</span></div>
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7600000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	26400000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. The Company’s standard payment terms are 30 days’.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue earned in connection with the license and services provided to customers and grantors. The Company provides credit to the grantors in the normal course of providing such services based on evaluations of their financial condition and generally does not require collateral. To manage accounts receivable credit risk, the Company monitors the creditworthiness of its grantors. Historically, the Company has not experienced any credit losses related to accounts receivable and does not maintain allowances for uncollectible amounts.</span></div>
CY2023	brns	Accounts Receivable Standard Payment Terms Period AccountsReceivableStandardPaymentTermsPeriod	P30D
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Intangible Assets Finite Lived Policy Costs Incurred To Renew Or Extend IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent and licensing costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patent and licensing costs are expensed as incurred because their realization is uncertain.</span></div>
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	brns	Research And Development Incentive Income Expense ResearchAndDevelopmentIncentiveIncomeExpense	3500000	usd
CY2022	brns	Research And Development Incentive Income Expense ResearchAndDevelopmentIncentiveIncomeExpense	1200000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38169307	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.91
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7600000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	26400000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-73347000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	5342000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38386491	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37248126	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	921181	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38386491	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.91
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6207664	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2912756	shares
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15509000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9279000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3688000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1322000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11821000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7957000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3200000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3200000	usd
CY2023Q4	brns	Finite Lived Intangible Asset Expected Amortization Year Eight FiniteLivedIntangibleAssetExpectedAmortizationYearEight	3200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3200000	usd
CY2023Q4	brns	Finite Lived Intangible Asset Expected Amortization Year Seven FiniteLivedIntangibleAssetExpectedAmortizationYearSeven	3200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3200000	usd
CY2023Q4	brns	Finite Lived Intangible Asset Expected Amortization Year Six FiniteLivedIntangibleAssetExpectedAmortizationYearSix	3200000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5402000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5887000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	3031000	usd
CY2023Q4	brns	Maximum Aggregate Nominal Amount Of Shares Authorized To Be Allotted Free From Statutory Pre Emption Rights MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights	1928	gbp
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	0	usd
CY2023Q4	brns	Lease Incentive Receivables Current LeaseIncentiveReceivablesCurrent	0	usd
CY2022Q4	brns	Lease Incentive Receivables Current LeaseIncentiveReceivablesCurrent	1770000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1474000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	611000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9907000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8268000	usd
CY2023Q4	brns	Accrued Manufacturing And Clinical Expenses Current AccruedManufacturingAndClinicalExpensesCurrent	4003000	usd
CY2022Q4	brns	Accrued Manufacturing And Clinical Expenses Current AccruedManufacturingAndClinicalExpensesCurrent	2997000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2412000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1925000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	789000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	928000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	942000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1270000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1066000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	941000	usd
CY2023Q4	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	9212000	usd
CY2022Q4	brns	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	8061000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	182000	usd
CY2023	brns	Contract With Customer Liability Revenue Recognized1 ContractWithCustomerLiabilityRevenueRecognized1	0	usd
CY2022	brns	Contract With Customer Liability Revenue Recognized1 ContractWithCustomerLiabilityRevenueRecognized1	158000	usd
CY2023	brns	Contract With Customer Liability Foreign Exchange Translation ContractWithCustomerLiabilityForeignExchangeTranslation	0	usd
CY2022	brns	Contract With Customer Liability Foreign Exchange Translation ContractWithCustomerLiabilityForeignExchangeTranslation	-24000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2023Q4	brns	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	vote
CY2023Q4	brns	Percentage Of Shares Necessary To Exercise Preemptive Rights PercentageOfSharesNecessaryToExercisePreemptiveRights	0.75
CY2023	brns	Period Of Preemptive Rights To Be Exercised PeriodOfPreemptiveRightsToBeExercised	P5Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6207664	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1623840	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7831504	shares
CY2022Q4	us-gaap	Goodwill Goodwill	12209000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	12630000	usd
CY2023	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	0	usd
CY2022	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-421000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	12209000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	12209000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4884720	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.04
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M9D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2619000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2288236	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.51
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	72386	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00026
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	892906	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.30
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6207664	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.91
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6044000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2839791	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.91
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y3M29D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2883000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.99
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.51
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	800000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3000000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	7100000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5055000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9877000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-50534000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	15511000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76522000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	850000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3075000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4471000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2352
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.1900
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0103
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-1.0346
CY2023	brns	Effective Income Tax Rate Reconciliation Provision To Return Adjustments EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments	-0.0409
CY2022	brns	Effective Income Tax Rate Reconciliation Provision To Return Adjustments EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustments	-1.0566
CY2023	brns	Effective Income Tax Rate Reconciliation Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment	0.0494
CY2022	brns	Effective Income Tax Rate Reconciliation Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment	3.0709
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0123
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-1.4982
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1184
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1.4655
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.0084
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.1021
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0407
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-5.1069
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23589000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9940000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	40000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3146000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	54000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4226000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3956000	usd
CY2023Q4	brns	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	3404000	usd
CY2022Q4	brns	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	2257000	usd
CY2023Q4	brns	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Intangibles DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles	745000	usd
CY2022Q4	brns	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Intangibles DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsIntangibles	765000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4228000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2522000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	36233000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22641000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25057000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13707000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11176000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8934000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1652000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1704000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1922000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1993000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	1267000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	1204000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	6909000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	7779000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	11750000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12680000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	574000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3746000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4200000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2500000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13707000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13500000	usd
CY2023	brns	Valuation Allowance Deferred Tax Asset Increase Resulting From Current Period Additions ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions	1052000	usd
CY2022	brns	Valuation Allowance Deferred Tax Asset Increase Resulting From Current Period Additions ValuationAllowanceDeferredTaxAssetIncreaseResultingFromCurrentPeriodAdditions	0	usd
CY2023	brns	Valuation Allowance Deferred Tax Asset Increase Resulting From Income Tax Provision ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision	9605000	usd
CY2022	brns	Valuation Allowance Deferred Tax Asset Increase Resulting From Income Tax Provision ValuationAllowanceDeferredTaxAssetIncreaseResultingFromIncomeTaxProvision	1500000	usd
CY2023	brns	Valuation Allowance Deferred Tax Asset Increase Decrease Resulting From Foreign Currency Translation ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation	693000	usd
CY2022	brns	Valuation Allowance Deferred Tax Asset Increase Decrease Resulting From Foreign Currency Translation ValuationAllowanceDeferredTaxAssetIncreaseDecreaseResultingFromForeignCurrencyTranslation	-1293000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25057000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13707000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	92700000	usd
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	40000.00	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	39600000	usd
CY2022	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	35100000	usd
CY2022Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	3100000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7581000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7753000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1785000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	433000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11191000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8340000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	639000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1081000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y11M4D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y5M8D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.075
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.076
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	189000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	529000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	883000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1216000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1072000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1745000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1785000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1936000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1960000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1985000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2010000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7999000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	17675000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4699000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	12976000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000	usd

Files In Submission

Name	View Source	Status
0001828185-24-000011-index-headers.html	Edgar Link	pending
0001828185-24-000011-index.html	Edgar Link	pending
0001828185-24-000011.txt	Edgar Link	pending
0001828185-24-000011-xbrl.zip	Edgar Link	pending
annexev6a.jpg	Edgar Link	pending
brns-20231231.htm	Edgar Link	pending
brns-20231231.xsd	Edgar Link	pending
brns-20231231xex1018.htm	Edgar Link	pending
brns-20231231xex211.htm	Edgar Link	pending
brns-20231231xex231.htm	Edgar Link	pending
brns-20231231xex311.htm	Edgar Link	pending
brns-20231231xex312.htm	Edgar Link	pending
brns-20231231xex321.htm	Edgar Link	pending
brns-20231231_g1.jpg	Edgar Link	pending
brns-20231231_g10.jpg	Edgar Link	pending
brns-20231231_g11.jpg	Edgar Link	pending
brns-20231231_g12.gif	Edgar Link	pending
brns-20231231_g2.jpg	Edgar Link	pending
brns-20231231_g3.jpg	Edgar Link	pending
brns-20231231_g4.jpg	Edgar Link	pending
brns-20231231_g5.jpg	Edgar Link	pending
brns-20231231_g6.jpg	Edgar Link	pending
brns-20231231_g7.jpg	Edgar Link	pending
brns-20231231_g8.gif	Edgar Link	pending
brns-20231231_g9.gif	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
image_1a.jpg	Edgar Link	pending
image_2a.jpg	Edgar Link	pending
image_3a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
brns-20231231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
brns-20231231_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
brns-20231231_pre.xml	Edgar Link	unprocessable
brns-20231231_cal.xml	Edgar Link	unprocessable
brns-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRNS
Barinthus Biotherapeutics plc. Stock $brns

2024 Q1 Form 10-K Financial Statement

#000182818524000011 Filed on March 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRNS Barinthus Biotherapeutics plc. Stock $brns

2024 Q1 Form 10-K Financial Statement

#000182818524000011 Filed on March 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRNS
Barinthus Biotherapeutics plc. Stock $brns